HemosIL Liquid Anti-Xa

FDA 510(k) K223187 · Instrumentation Laboratory CO

Substantially Equivalent

510(k) numberK223187

Submission

Device name
HemosIL Liquid Anti-Xa
Applicant
Instrumentation Laboratory CO
Bedford, MA, US
Received
October 12, 2022
Decision date
June 23, 2023
Decision
Substantially Equivalent (SESE)
Type
Traditional 510(k)
Summary
510(k) summary available from FDA

Official FDA 510(k) record

Device classification

Product code
QLU – Anti-Factor Xa Activity Test System, Apixaban
Device class
Class II (moderate risk)
Regulation
21 CFR 864.7295
Specialty
Hematology

A heparin and direct oral factor Xa inhibitor drug test system is intended for the detection of heparin and direct oral factor Xa inhibitors in human specimens collected from patients taking heparin or direct oral factor Xa inhibitors. This device is intended to aid in the management of therapy in conjunction with other clinical and laboratory findings.

Other 510(k)s with product code QLU

510(k)DeviceApplicantDecision
K240315INNOVANCE Anti-Xa (OPPU05); INNOVANCE Apixaban Standards (OPPW05); INNOVANCE Apixaban…QLU · Traditional Siemens Healthcare Diagnostics Products GmbH10/10/2024SE

More from Siemens Healthcare Diagnostics Products GmbH

510(k)DeviceDecision
K233790Acl Top 970 CLJPA · Special 12/29/2023SE
K230852HemosIL Chromogenic Factor IXGGP · Traditional 12/13/2023SE
K221359ACL TOP 970 CL, HemosIL CL Anti-Cardiolipin IgM, HemosIL CL Anti-ß2 Glycoprotein-I IgMJPA · Traditional 09/29/2023SE
K223608GEM Premier 7000 with IQM3CHL · Traditional 08/10/2023SE
K231031ACL TOP Family 70 SeriesGKP · Traditional 06/21/2023SE
K223090GEM Premier ChemSTATCGA · Special 01/27/2023SE
K223402HemosIL von Willebrand Factor AntigenGGP · Special 12/09/2022SE
K213464HemosIL Liquid Anti-XaKFF · Special 10/04/2022SE
K213426HemosIL ReadiPlasTinGJS · Traditional 08/16/2022SE
K203790GEM Premier 5000CHL · Special 08/20/2021SE

Questions and answers

When was HemosIL Liquid Anti-Xa cleared by the FDA?

HemosIL Liquid Anti-Xa (K223187) received a 510(k) decision of Substantially Equivalent on June 23, 2023, 254 days after the submission was received.

What is the product code of K223187?

The FDA product code is QLU – Anti-Factor Xa Activity Test System, Apixaban, a Class II (moderate risk) device regulated under 21 CFR 864.7295.